TLP
CLDX icon

Tri Locum Partners’s Celldex Therapeutics CLDX Stock Holding History

Tri Locum Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-176,109
Closed -$7.85M – 57
2022
Q4 		$7.85M Sell
176,109
-62,460
-26% -$2.23M 3.17% 11
2022
Q3 		$6.71M Buy
238,569
+106,421
+81% +$3.26M 1.84% 21
2022
Q2 		$3.56M Sell
132,148
-251,171
-66% -$7.29M 1.46% 22
2022
Q1 		$13.1M Buy
+383,319
New +$12.3M 5.1% 5
2021
Q3 		– Sell
-175,305
Closed -$5.86M – 32
2021
Q2 		$5.86M Sell
175,305
-21,367
-11% -$587K 1.92% 14
2021
Q1 		$4.05M Buy
+196,672
New +$4.52M 1% 20

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Tri Locum Partners's CLDX Position: Q1 2023 in Review

Tri Locum Partners sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 176,109 shares — an estimated $7.85M sold.

Tri Locum Partners first reported a position in CLDX in Q1 2021 and held it in 6 quarters. The position peaked at $13.1M in Q1 2022. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • Tri Locum Partners reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tri Locum Partners sold 176,109 Celldex Therapeutics shares in Q1 2023, an estimated $7.85M.
  • Tri Locum Partners first reported a position in Celldex Therapeutics in Q1 2021 and held it in 6 quarters.
  • Tri Locum Partners's Celldex Therapeutics position peaked at $13.1M in Q1 2022.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.